GA NCORP

NCORP Trials

A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®14045 in Patients With CD123-Expressing Hematologic Malignancies

Status
Active
Cancer Type
Leukemia
Lymphoma
Myelodysplastic Syndromes (MDS)
Skin Cancer (Non-Melanoma)
Trial Phase
Phase I
Eligibility
18 Years and older, Male and Female
Study Type
Treatment
NCD ID
NCT02730312
Protocol IDs
XmAb14045-01 (primary)
NCI-2016-00916
Study Sponsor
Xencor, Inc.

Summary

The purpose of this study is to determine the safety and tolerability of weekly intravenous (IV) administration of XmAb14045 and to determine the maximally tolerated dose (MTD) after the first dose, and then to determine the MTD after second and subsequent infusions.

Treatment Sites


Northside Hospital Cancer Institute
1000 Johnson Ferry Road NE
Atlanta, GA 30342
Northside Hospital Central Research Department
404-303-3355
www.northside.com

 
For a complete listing of all trial sites in Georgia, please visit GeorgiaCancerInfo.org